Stocks · News reference
BTIG analyst Jeet Mukherjee reiterates Ascentage Pharma Group (NASDAQ:AAPG) with a Buy and maintains $48 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Ascentage Pharma Group (NASDAQ:AAPG) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzingaAscentage Pharma announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and US commercialization efforts. Both executives bring extensive experience in oncology and specialty therapeutics, with the company advancing multiple Phase III registrational studies for its pipeline of cancer therapies.
Read original at globenewswire-inc